Top U.S. Health Official Backed a Medication Policy Shift That Benefited a Company She Has Stock In by Corey G. Johnson and Brandon Roberts October 29, 2026, 5:30 am

Top U.S. Health Official Backed a Medication Policy Shift That Benefited a Company She Has Stock In Alicia Jackson endorsed a key FDA policy change on hormone replacement therapies while holding at least $115,000 in stock in a company providing access to menopause treatments. Ethics experts called her endorsement an “obvious conflict of interest.” by Corey G. Johnson and Brandon Roberts October 29, 2026, 5:30 am https://www.propublica.org/article/hhs-alicia-jackson-menopause-treatment-policy